RGD Reference Report - Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.

Authors: Cabezudo, E  Carrara, P  Morilla, R  Matutes, E 
Citation: Cabezudo E, etal., Haematologica. 1999 May;84(5):413-8.
RGD ID: 11531139
Pubmed: PMID:10329919   (View Abstract at PubMed)

BACKGROUND AND OBJECTIVE: Distinction between B-cell chronic leukemias can be difficult due to overlap in cell morphology and immunologic features. We investigated, by quantitative flow cytometry, the expression of CD79b, CD5 and CD19 in cells from a variety of B-cell disorders to see whether this analysis adds further information useful to the diagnosis and characterization of these diseases. DESIGN AND METHODS: Peripheral blood cells from 6 normal individuals were used as reference controls. The diseases of the 63 patients investigated comprised: 29 chronic lymphocytic leukemia (CLL), six of them with atypical morphology, 6 B-cell prolymphocytic leukemia (PLL), 12 splenic lymphoma with villous lymphocytes (SLVL) and 16 mantle-cell (Mc) lymphoma in leukemic phase. The study was carried out by triple immunostaining with directly conjugated monoclonal antibodies (MoAb) against CD79b, CD5 and CD19 and quantitative estimation of the antigens per cell assessed with standard microbeads (Quantum Simply Cellular). RESULTS: Compared to normal B-cells, the number of CD19 molecules was significantly lower in cells from all of the B-cell disorders except PLL. The intensity of CD5 in leukemic B-cells was significantly higher in CLL cells, including atypical cases, and Mc lymphoma than in normal B-cells, whilst PLL and SLVL had values similar to those of normal B-lymphocytes. CD79b was expressed at lower levels in all types of leukemic cells compared to normal B-lymphocytes but differences were statistically significant in CLL, Mc lymphoma and SLVL. The number of CD79b molecules per cell was significantly lower in typical CLL than in the remaining B-cell diseases whilst the comparison of CD5 and CD19 intensity between CLL and non-CLL samples failed to show any statistically significant difference. INTERPRETATION AND CONCLUSIONS: Distinct antigen density patterns for the various conditions emerged from this analysis: Typical CLL was characterized by moderate CD5 and weak or negative CD79b expression. Mc lymphoma showed an homogeneous pattern, characterized by similar expression of CD5 than CLL but significantly stronger expression of CD79b whilst PLL and SLVL had weak CD5 and moderate CD79b expression. Atypical CLL had an intermediate pattern of CD79b antigen expression ranging from weak to moderate with bright CD5. Unlike CD5 and CD79b, CD19 did not discriminate the various B-cell disorders but only between normal and leukemic cells.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CD79BHumanchronic lymphocytic leukemia  IEP protein:decreased expression:blood and B cell (human)RGD 
Cd79bRatchronic lymphocytic leukemia  ISOCD79B (Homo sapiens)protein:decreased expression:blood and B cell (human)RGD 
Cd79bMousechronic lymphocytic leukemia  ISOCD79B (Homo sapiens)protein:decreased expression:blood and B cell (human)RGD 
CD79BHumanmantle cell lymphoma  IEP protein:decreased expression:blood and B cell (human)RGD 
Cd79bRatmantle cell lymphoma  ISOCD79B (Homo sapiens)protein:decreased expression:blood and B cell (human)RGD 
Cd79bMousemantle cell lymphoma  ISOCD79B (Homo sapiens)protein:decreased expression:blood and B cell (human)RGD 
CD79BHumansplenic marginal zone lymphoma  IEP protein:decreased expression:blood and B cell (human)RGD 
Cd79bRatsplenic marginal zone lymphoma  ISOCD79B (Homo sapiens)protein:decreased expression:blood and B cell (human)RGD 
Cd79bMousesplenic marginal zone lymphoma  ISOCD79B (Homo sapiens)protein:decreased expression:blood and B cell (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Cd79b  (CD79b molecule)

Genes (Mus musculus)
Cd79b  (CD79B antigen)

Genes (Homo sapiens)
CD79B  (CD79b molecule)


Additional Information